Metformin and GLP-1s Together: What the Trials Show About Weight, Blood Sugar, B12, and Side Effects

Metformin has been prescribed for more than 60 years and costs a few dollars a month. Semaglutide and tirzepatide are the newest metabolic drugs on the market. A lot of people end up taking both.

That pairing is not an experiment. Metformin is the usual first medicine for type 2 diabetes, so nearly every major GLP-1 diabetes trial enrolled people who were already on it. The data on how the two behave together is large and fairly consistent. What is less clear is whether metformin adds much for someone using a GLP-1 mainly for weight or body composition, and whether a microdose protocol changes the picture.

This article covers what metformin does on its own, what the combination trials measured, where the side effects overlap, and the three monitoring points that matter most: vitamin B12, kidney function, and hydration during illness.

How do metformin and GLP-1 medicines work differently?

Liver first versus gut, pancreas, and brain

Metformin mainly lowers the amount of glucose the liver releases, while GLP-1 medicines act on the pancreas, stomach, and brain. Metformin reduces hepatic gluconeogenesis, improves insulin sensitivity modestly, and acts in the gut, where it changes bile acid handling and the microbiome. Metformin also raises levels of GDF15, a hormone that suppresses appetite through the brainstem; Coll and colleagues reported in Nature in 2020 that GDF15 accounts for much of metformin's small weight effect in mice.

GLP-1 receptor agonists such as semaglutide increase insulin secretion only when glucose is raised, suppress glucagon, slow gastric emptying, and reduce appetite through receptors in the hypothalamus and brainstem. Tirzepatide adds GIP receptor activity on top. Because the two drug classes work through different pathways, their effects on blood glucose add together in trials, while their effects on body weight are dominated by the GLP-1.

How much weight does metformin cause compared with a GLP-1?

A few percent versus fifteen to twenty

Metformin causes modest weight loss of roughly 2 percent of body weight, which is far smaller than the loss seen on full dose GLP-1 medicines. In the Diabetes Prevention Program, 3,234 adults with prediabetes took metformin 850 mg twice daily, placebo, or an intensive lifestyle program. After an average of 2.8 years, the metformin group had lost about 2.1 kg, the placebo group 0.1 kg, and the lifestyle group 5.6 kg.

Semaglutide 2.4 mg produced an average loss of 14.9 percent over 68 weeks in STEP 1, and tirzepatide 15 mg produced 20.9 percent over 72 weeks in SURMOUNT-1. Those are different populations and trial lengths, so the chart below is a rough scale comparison, not a head to head result. The point it makes is simple: for weight, metformin is a minor contributor next to a GLP-1.

Does metformin prevent type 2 diabetes?

It lowered incidence by 31 percent in the DPP

Metformin reduced the incidence of type 2 diabetes by 31 percent compared with placebo in the Diabetes Prevention Program, published in the New England Journal of Medicine in 2002. The intensive lifestyle program, which targeted 7 percent weight loss and 150 minutes of weekly activity, did better, with a 58 percent reduction. Diabetes developed at 11.0 cases per 100 person-years on placebo, 7.8 on metformin, and 4.8 with lifestyle change.

Metformin's benefit in the DPP was largest in people under 60, those with a BMI of 35 or higher, and women with a history of gestational diabetes. The follow up study, DPPOS, has now tracked these participants for more than 20 years. GLP-1 medicines have their own prevention data: in STEP 1, most participants with prediabetes at baseline returned to normal glucose on semaglutide 2.4 mg.

What happens when a GLP-1 is added to metformin?

Large extra drops in HbA1c and weight

Adding a GLP-1 medicine to metformin produces large additional drops in HbA1c and body weight in people with type 2 diabetes. The clearest example is SURPASS-2, published by Frias and colleagues in the New England Journal of Medicine in 2021. The trial randomised 1,879 adults already taking at least 1,500 mg of metformin a day to tirzepatide 5, 10, or 15 mg or semaglutide 1 mg for 40 weeks.

From a starting HbA1c of about 8.3 percent, semaglutide 1 mg lowered HbA1c by 1.86 points and tirzepatide by 2.01 to 2.30 points. Weight fell by 5.7 kg on semaglutide and by 7.6 to 11.2 kg on tirzepatide. The SUSTAIN program for semaglutide and the LEAD program for liraglutide produced the same broad pattern: metformin stayed in place as the foundation, and the GLP-1 did most of the additional work.

Are stomach side effects worse when metformin and a GLP-1 are combined?

They can stack, especially at the start

Stomach side effects can be worse on the combination because metformin and GLP-1 medicines both cause nausea, diarrhoea, and abdominal discomfort. Metformin's gastrointestinal effects affect roughly one in four people when it is started, are usually worst in the first few weeks, and are reduced by taking it with meals and by using the extended release form. GLP-1 side effects peak during dose escalation.

In SURPASS-2, where everyone was already on metformin and presumably tolerating it, nausea was reported by about 17 to 22 percent of people on tirzepatide and 18 percent on semaglutide 1 mg. A common clinical approach is to change one drug at a time: stabilise metformin first, then start the GLP-1, and avoid raising both doses in the same week. That way, if diarrhoea appears, it is clear which drug is responsible.

Does the combination cause low blood sugar?

Rarely, unless insulin or a sulfonylurea is involved

Metformin combined with a GLP-1 medicine rarely causes low blood sugar on its own. GLP-1 drugs stimulate insulin only when glucose is above normal, and metformin does not stimulate insulin release at all. In SURPASS-2, clinically significant hypoglycemia below 54 mg/dL occurred in under 2 percent of participants in any arm.

The picture changes when a sulfonylurea such as glipizide or glimepiride, or insulin, is also part of the regimen. Those drugs push insulin up regardless of glucose, and prescribers commonly reduce their dose when a GLP-1 is added. The hypoglycemia article on this site covers the symptoms and the glucose thresholds in more detail.

Why does vitamin B12 matter on metformin and a GLP-1?

Two routes to a lower level

Vitamin B12 matters because long term metformin use lowers B12 levels, and eating less on a GLP-1 can lower B12 intake at the same time. Metformin interferes with calcium dependent B12 absorption in the terminal ileum. In the DPP Outcomes Study, Aroda and colleagues (Journal of Clinical Endocrinology and Metabolism, 2016) found low B12 in 4.3 percent of the metformin group versus 2.3 percent on placebo at year 5, and 7.4 versus 5.4 percent at year 13. Anaemia and peripheral neuropathy were more common in the metformin group.

The American Diabetes Association Standards of Care recommend periodic B12 measurement in people on metformin, particularly those with neuropathy or anaemia. On a GLP-1, total food intake often falls by 20 to 40 percent, and meat, eggs, and dairy are the main dietary sources of B12. The micronutrient article on this site covers B12, iron, and folate testing on a GLP-1 in more depth.

What should you know about kidney function and sick days?

Dehydration links the two drugs

Kidney function matters for this combination because metformin is cleared by the kidneys and GLP-1 stomach side effects can cause dehydration. The FDA metformin labelling says metformin is contraindicated when eGFR is below 30 mL/min/1.73 m², should not be started when eGFR is between 30 and 45, and should be reassessed if eGFR falls below 45 during treatment. The feared complication, lactic acidosis, is rare, at roughly 3 to 10 cases per 100,000 patient-years, but it is linked to poor kidney clearance and dehydrating illness.

GLP-1 labels separately warn that acute kidney injury has been reported in people who became dehydrated from nausea, vomiting, or diarrhoea. Many clinicians give a written sick day plan that pauses metformin during vomiting or diarrhoea and restarts it once eating and drinking return to normal, plus guidance on whether to delay the next GLP-1 dose. Contrast scans and surgery are other occasions when metformin is commonly paused.

Does metformin interfere with training and muscle gain?

Possibly, in older adults without diabetes

Metformin may blunt some training adaptations, according to two small trials in older adults without diabetes. In the MASTERS trial (Walton et al., Aging Cell, 2019), adults aged 65 and over did 14 weeks of progressive resistance training while taking 1,700 mg of metformin or placebo. The metformin group gained less lean mass and thigh muscle. Konopka and colleagues (Aging Cell, 2019) found that metformin blunted the improvement in whole body insulin sensitivity and muscle mitochondrial respiration after 12 weeks of aerobic training.

These findings matter for anyone using a GLP-1 protocol with a body recomposition goal, because lean mass preservation already takes deliberate effort during weight loss. The trials were small and did not include people with diabetes, where metformin's glucose benefits are established. They are a reason to discuss the trade off with a prescriber, not a reason to stop a prescribed medicine.

Does metformin make sense alongside a microdose GLP-1 protocol?

Untested, and the rationale depends on the person

Whether metformin makes sense alongside a microdose GLP-1 protocol has not been tested in any clinical trial. All of the combination data above comes from full dose diabetes studies, where metformin was the starting treatment and the GLP-1 was added on top. For someone with type 2 diabetes or prediabetes, metformin may already be part of the plan for good reasons, and a lower GLP-1 dose would sit on top of it in the usual way.

For someone without diabetes using a low dose GLP-1 for appetite or body composition, the case for adding metformin is thinner. Its weight effect is small, it adds its own stomach side effects, it can lower B12 over time, and it may blunt some training gains. Metformin is also discussed as a longevity drug, but the TAME trial designed to test that has not reported results, and observational data are mixed.

One practical point does apply at any dose: introduce changes one at a time. A microdose protocol that is going well is easy to misread if metformin is started the same week.

What should be monitored on metformin plus a GLP-1?

Five checks worth discussing with a prescriber

Monitoring on metformin plus a GLP-1 centres on kidney function, B12, glucose control, and hydration. The list below summarises what guidelines and labels mention.

Frequently Asked Questions